Quark Pharmaceuticals Inc

quarkpharma.com

Quark Pharmaceuticals, Inc., the world leader in novel therapeutic RNAi discovery and development, has the largest clinical-stage siRNA pipeline in the industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

WAREHOUSE OPTIMIZATION HELPED A PHARMA COMPANY TO INTEGRATE DATA FROM DISPARATE SOURCE WITHIN THE SUPPLY CHAIN

Businesswire | May 07, 2020

news image

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of its recent engagement which examines the role of warehouse optimization in the pharma industry. This success story offers comprehensive insights into how Quantzig helped a pharma company who was facing a multitude of warehouse optimization and distribution challenges that were further complicated by the nature of the drugs that the...

Read More

GUERBET (GBT) TO SALE ITS PHARMACEUTICAL SITE IN MONTREAL (CANADA) TO MEDXL

Guerbet, MedXL | July 16, 2020

news image

Guerbet (GBT) today announced the sale of its pharmaceutical site in Montreal (Canada) to MedXL, a specialist in medical devices and sterile pre-filled syringes. The Montreal industrial facility specializes on the one hand in filling and finishing of contrast media and on the other in the large-series manufacture of syringes pre-filled with sterile solutions for third parties, which is not a core business for Guerbet. Guerbet will gradually transfer its contrast agent production, ...

Read More

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

HIT Consultant | April 07, 2020

news image

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

RESEARCH

GILEAD GETS WHO COLD SHOULDER FOR REMDESIVIR IN COVID-19, LAUNCHES SPEEDY DEFENSE

Gilead | November 21, 2020

news image

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect...

Read More
news image

WAREHOUSE OPTIMIZATION HELPED A PHARMA COMPANY TO INTEGRATE DATA FROM DISPARATE SOURCE WITHIN THE SUPPLY CHAIN

Businesswire | May 07, 2020

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of its recent engagement which examines the role of warehouse optimization in the pharma industry. This success story offers comprehensive insights into how Quantzig helped a pharma company who was facing a multitude of warehouse optimization and distribution challenges that were further complicated by the nature of the drugs that the...

Read More
news image

GUERBET (GBT) TO SALE ITS PHARMACEUTICAL SITE IN MONTREAL (CANADA) TO MEDXL

Guerbet, MedXL | July 16, 2020

Guerbet (GBT) today announced the sale of its pharmaceutical site in Montreal (Canada) to MedXL, a specialist in medical devices and sterile pre-filled syringes. The Montreal industrial facility specializes on the one hand in filling and finishing of contrast media and on the other in the large-series manufacture of syringes pre-filled with sterile solutions for third parties, which is not a core business for Guerbet. Guerbet will gradually transfer its contrast agent production, ...

Read More
news image

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

HIT Consultant | April 07, 2020

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More
news image

RESEARCH

GILEAD GETS WHO COLD SHOULDER FOR REMDESIVIR IN COVID-19, LAUNCHES SPEEDY DEFENSE

Gilead | November 21, 2020

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect...

Read More